Additionally, EU-RESPONSE has built a new multinational European Adaptive Platform Trial, based on existing initiatives, experiences and competencies – this platform trial is EU-SolidAct. This is a flexible platform, providing a modular trial network enabling European hospitals to participate at the level of commitment that aligns with their capacity. Data collection ranges from clinical assessment parameters to PROMs and advanced biobanking.
EU-SolidAct will aim to run repurposing trials, evaluating combination strategies as well as evaluating efficacy and safety of new compounds entering clinical development on COVID 19″. The platform trial has the capacity for running both phase 2 and phase 3 trials. EU-SolidAct is designed to enable rapid reactivation in case of emerging infectious diseases and new epidemics.
The project also includes a coordination module with the EU-funded RECOVER project, led by ECRIN, ensuring complementarity and cooperation across all large European COVID-19 Adaptive Platform trials, and their capacity to answer the needs of society through dialogue with the EMA, national competent authorities, HTAs and industry partners.
Although in the short-term this project will focus on COVID-19, the mid- and long-term objectives are to build a platform trial network on emerging infectious diseases in general.